Gastric Cancer – Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs :Frontier Pharma
“The Report Frontier Pharma: Gastric Cancer – Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”
Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients. As the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a gradual shift from generic cytotoxic therapies to more diverse targeted therapies.
View Report At :http://www.marketresearchreports.biz/analysis/713902
What is the pathophysiology of gastric cancer?
How is gastric cancer diagnosed?
What are the current treatment options?
What are the common targets and mechanisms of action of pipeline therapies?
Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
What implications will the increased focus on targeted therapies have on the future of gastric cancer treatment?
What are the most promising first-in-class targets for gastric cancer?
Will the current first-in-class targets have a broader therapeutic potential across the industry?
How do deal frequency and value compare between target families and molecule types?
How do licensing and co-development deals compare between first-in-class and non-first-in-class profiles?
Reasons to buy
Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies
Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
Analyze the gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating gastric cancer.
Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals and producing a list of gastric cancer therapies that are not yet involved in deals, and may be potential investment opportunities.
Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/713902
Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 Significant Unmet Needs in the Gastric Cancer Market 4
2.2 High Proportion of First-in-Class Innovation Offers Promise in Gastric Cancer 4
2.3 Deal Activity Varies with First-in-Class Status 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Development Remains Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Disease Symptoms 9
4.3 Epidemiology and Etiology 9
4.4 Pathophysiology 9
4.4.1 Helicobacter Pylori 10
4.4.2 Oncogenes 10
4.4.3 Tumor Suppressor Genes 10
4.4.4 Cell Adhesion Molecules and Metastasis-Related Genes 10
4.4.5 Cell Cycle Regulators 10
4.4.6 Microsatellite and Chromosomal Instability 10
4.4.7 Growth Factor and Cytokines 11
4.5 Diagnosis and Staging 11
4.6 Classification 12
4.6.1 Intestinal Subtype 12
4.6.2 Diffuse Subtype 12
4.7 Prognosis 12
4.8 Treatment Options 13
4.8.1 Surgery 13
4.8.2 First-Line Therapy 13
4.8.3 Second-Line Therapy 16
4.9 Overview of Marketed Products in Gastric Cancer 17
4.9.1 Molecule Type and Target Analysis 17
4.9.2 Innovative Products in Gastric Cancer Market 19
4.9.3 Unmet Needs 19
5 Assessment of Pipeline Product Innovation 20
5.1 Gastric Cancer Pipeline by Molecule Type, Phase and Therapeutic Target 20
5.2 Comparative Distribution of Programs between the Gastric Cancer Market and Pipeline by Therapeutic Target Family 24
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 24
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207